Evaluation of Chemotherapeutic Drugs for Treatment of (Cisplatin-Resistant) Germ Cell Cancer Cell Lines.
Apoptosis
Cell cycle
Cell viability
Germ cell cancers
Journal
Methods in molecular biology (Clifton, N.J.)
ISSN: 1940-6029
Titre abrégé: Methods Mol Biol
Pays: United States
ID NLM: 9214969
Informations de publication
Date de publication:
2021
2021
Historique:
entrez:
28
8
2020
pubmed:
28
8
2020
medline:
25
3
2021
Statut:
ppublish
Résumé
Cisplatin resistance still remains a major obstacle in the standard chemotherapeutic approach in late-stage and metastatic testicular germ cell cancer (GCC) patients. This multifactorial and complex phenomenon arises (concomitantly) on several levels due to impaired transport, decreased adduct formation, increased DNA-repair, decreased apoptosis, or compensating pathways. Evaluation of novel therapeutic approaches and pharmacological inhibitors still remains necessary to treat cisplatin-resistant GCCs. In this chapter, we present in vitro techniques to measure cytotoxic impacts of chemotherapeutic drugs on GCC cell lines. Specifically, we will discuss the measurement of relative cell viability by XTT assay, as well as cell cycle distribution and apoptosis assay by Nicoletti- and Annexin V/PI apoptosis assay with subsequent flow cytometry, respectively, to evaluate the effects of cytotoxic treatment in GCC cell lines.
Identifiants
pubmed: 32852760
doi: 10.1007/978-1-0716-0860-9_8
doi:
Substances chimiques
Antineoplastic Agents
0
Cisplatin
Q20Q21Q62J
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
99-111Références
Cheng L, Albers P, Berney DM, Feldman DR, Daugaard G, Gilligan T, Looijenga LHJ (2018) Testicular cancer. Nat Rev Dis Primers 4(1):29. https://doi.org/10.1038/s41572-018-0029-0
Feldman DR (2015) Update in germ cell tumours. Curr Opin Oncol 27(3):177–184. https://doi.org/10.1097/CCO.0000000000000179
doi: 10.1097/CCO.0000000000000179
pubmed: 25850580
Walker MC, Povey S, Parrington JM, Riddle PN, Knuechel R, Masters JR (1990) Development and characterization of cisplatin-resistant human testicular and bladder tumour cell lines. Eur J Cancer 26(6):742-747. https://doi.org/10.1016/0277-5379(90)90133-e
Jacobsen C, Honecker F (2015) Cisplatin resistance in germ cell tumours: models and mechanisms. Andrology 3(1):111–121. https://doi.org/10.1111/andr.299
doi: 10.1111/andr.299
pubmed: 25546083
Dasari S, Tchounwou PB (2014) Cisplatin in cancer therapy: molecular mechanisms of action. Eur J Pharmacol 740:364–378. https://doi.org/10.1016/j.ejphar.2014.07.025
doi: 10.1016/j.ejphar.2014.07.025
pubmed: 25058905
pmcid: 4146684
Piulats JM, Jimenez L, Garcia del Muro X, Villanueva A, Vinals F, Germa-Lluch JR (2009) Molecular mechanisms behind the resistance of cisplatin in germ cell tumours. Clin Transl Oncol 11(12):780–786. https://doi.org/10.1007/s12094-009-0446-3
doi: 10.1007/s12094-009-0446-3
pubmed: 20045784
Mayer F, Honecker F, Looijenga LH, Bokemeyer C (2003) Towards an understanding of the biological basis of response to cisplatin-based chemotherapy in germ-cell tumors. Ann Oncol 14(6):825–832. https://doi.org/10.1093/annonc/mdg242
Looijenga LH, Gillis AJ, Stoop H, Biermann K, Oosterhuis JW (2011) Dissecting the molecular pathways of (testicular) germ cell tumour pathogenesis; from initiation to treatment-resistance. Int J Androl 34(4 Pt 2):e234–e251. https://doi.org/10.1111/j.1365-2605.2011.01157.x
Oronsky B, Ray CM, Spira AI, Trepel JB, Carter CA, Cottrill HM (2017) A brief review of the management of platinum-resistant-platinum-refractory ovarian cancer. Med Oncol 34(6):103. https://doi.org/10.1007/s12032-017-0960-z
doi: 10.1007/s12032-017-0960-z
pubmed: 28444622
Zhu H, Luo H, Zhang W, Shen Z, Hu X, Zhu X (2016) Molecular mechanisms of cisplatin resistance in cervical cancer. Drug Des Devel Ther 10:1885–1895. https://doi.org/10.2147/DDDT.S106412
doi: 10.2147/DDDT.S106412
pubmed: 27354763
pmcid: 4907638
Chen X, Lu P, Wu Y, Wang DD, Zhou S, Yang SJ, Shen HY, Zhang XH, Zhao JH, Tang JH (2016) MiRNAs-mediated cisplatin resistance in breast cancer. Tumour Biol 37(10):12905–12913. https://doi.org/10.1007/s13277-016-5216-6
doi: 10.1007/s13277-016-5216-6
pubmed: 27448297
Chen Y, Gao Y, Zhang K, Li C, Pan Y, Chen J, Wang R, Chen L (2015) MicroRNAs as regulators of cisplatin resistance in lung cancer. Cell Physiol Biochem 37(5):1869–1880. https://doi.org/10.1159/000438548
Skowron MA, Melnikova M, van Roermund JGH, Romano A, Albers P, Thomale J, Schulz WA, Niegisch G, Hoffmann MJ (2018) Multifaceted mechanisms of cisplatin resistance in long-term treated urothelial carcinoma cell lines. Int J Mol Sci 19(2):590. https://doi.org/10.3390/ijms19020590
Sark MW, Timmer-Bosscha H, Meijer C, Uges DR, Sluiter WJ, Peters WH, Mulder NH, de Vries EG (1995) Cellular basis for differential sensitivity to cisplatin in human germ cell tumour and colon carcinoma cell lines. Br J Cancer 71(4):684–690. https://doi.org/10.1038/bjc.1995.173
doi: 10.1038/bjc.1995.173
pubmed: 7710929
pmcid: 2033748
Galluzzi L, Senovilla L, Vitale I, Michels J, Martins I, Kepp O, Castedo M, Kroemer G (2012) Molecular mechanisms of cisplatin resistance. Oncogene 31(15):1869–1883. https://doi.org/10.1038/Onc.2011.384
doi: 10.1038/Onc.2011.384
pubmed: 21892204
Chin JL, Banerjee D, Kadhim SA, Kontozoglou TE, Chauvin PJ, Cherian MG (1993) Metallothionein in testicular germ cell tumors and drug resistance: clinical correlation. Cancer 72(10):3029–3035. https://doi.org/10.1002/1097-0142(19931115)72:10<3029::AID-CNCR2820721027>3.0.CO;2-6
Tuzel E, Yorukoglu K, Ozkara E, Kirkali Z (2015) Association of metallothionein expression and clinical response to cisplatin based chemotherapy in testicular germ cell tumors. Cent European J Urol 68(1):45–50. https://doi.org/10.5173/ceju.2015.01.486
Meijer C, Timmer A, De Vries EG, Groten JP, Knol A, Zwart N, Dam WA, Sleijfer DT, Mulder NH (2000) Role of metallothionein in cisplatin sensitivity of germ-cell tumours. Int J Cancer 85(6):777–781. https://doi.org/10.1002/(SICI)1097-0215(20000315)85:6<777::AID-IJC6>3.0.CO;2-D
doi: 10.1002/(SICI)1097-0215(20000315)85:6<777::AID-IJC6>3.0.CO;2-D
pubmed: 10709094
Reed E (1998) Platinum-DNA adduct, nucleotide excision repair and platinum based anti-cancer chemotherapy. Cancer Treat Rev 24(5):331–344. https://doi.org/10.1016/S0305-7372(98)90056-1
doi: 10.1016/S0305-7372(98)90056-1
pubmed: 9861196
Koberle B, Grimaldi KA, Sunters A, Hartley JA, Kelland LR, Masters JR (1997) DNA repair capacity and cisplatin sensitivity of human testis tumour cells. Int J Cancer 70(5):551–555. https://doi.org/10.1002/(SICI)1097-0215(19970304)70:5<551::AID-IJC10>3.0.CO;2-G
Koberle B, Masters JR, Hartley JA, Wood RD (1999) Defective repair of cisplatin-induced DNA damage caused by reduced XPA protein in testicular germ cell tumours. Curr Biol 9(5):273–276. https://doi.org/10.1016/S0960-9822(99)80118-3
Koberle B, Brenner W, Albers A, Usanova S, Thuroff JW, Kaina B (2010) ERCC1 and XPF expression in human testicular germ cell tumors. Oncol Rep 23(1):223–227. https://doi.org/10.3892/or_00000627
Usanova S, Piee-Staffa A, Sied U, Thomale J, Schneider A, Kaina B, Koberle B (2010) Cisplatin sensitivity of testis tumour cells is due to deficiency in interstrand-crosslink repair and low ERCC1-XPF expression. Mol Cancer 9:248. https://doi.org/10.1186/1476-4598-9-248
Kothandapani A, Sawant A, Dangeti VS, Sobol RW, Patrick SM (2013) Epistatic role of base excision repair and mismatch repair pathways in mediating cisplatin cytotoxicity. Nucleic Acids Res 41(15):7332–7343. https://doi.org/10.1093/nar/gkt479
doi: 10.1093/nar/gkt479
pubmed: 23761438
pmcid: 3753620
Honecker F, Wermann H, Mayer F, Gillis AJ, Stoop H, van Gurp RJ, Oechsle K, Steyerberg E, Hartmann JT, Dinjens WN, Oosterhuis JW, Bokemeyer C, Looijenga LH (2009) Microsatellite instability, mismatch repair deficiency, and BRAF mutation in treatment-resistant germ cell tumors. J Clin Oncol 27(13):2129–2136. https://doi.org/10.1200/JCO.2008.18.8623
Rudolph C, Melau C, Nielsen JE, Vile Jensen K, Liu D, Pena-Diaz J, Rajpert-De Meyts E, Rasmussen LJ, Jorgensen A (2017) Involvement of the DNA mismatch repair system in cisplatin sensitivity of testicular germ cell tumours. Cell Oncol (Dordr) 40(4):341–355. https://doi.org/10.1007/s13402-017-0326-8
Spierings DC, de Vries EG, Vellenga E, de Jong S (2003) Loss of drug-induced activation of the CD95 apoptotic pathway in a cisplatin-resistant testicular germ cell tumor cell line. Cell Death Differ 10(7):808–822. https://doi.org/10.1038/sj.cdd.4401248
Spierings DC, de Vries EG, Stel AJ, te Rietstap N, Vellenga E, de Jong S (2004) Low p21Waf1/Cip1 protein level sensitizes testicular germ cell tumor cells to Fas-mediated apoptosis. Oncogene 23(28):4862–4872. https://doi.org/10.1038/sj.onc.1207617
Scudiero DA, Shoemaker RH, Paull KD, Monks A, Tierney S, Nofziger TH, Currens MJ, Seniff D, Boyd MR (1988) Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines. Cancer Res 48(17):4827–4833
pubmed: 3409223
Nicoletti I, Migliorati G, Pagliacci MC, Grignani F, Riccardi C (1991) A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods 139(2):271–279. https://doi.org/10.1016/0022-1759(91)90198-O
Vermes I, Haanen C, Steffens-Nakken H, Reutelingsperger C (1995) A novel assay for apoptosis. Flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein labelled Annexin V. J Immunol Methods 184(1):39–51. https://doi.org/10.1016/0022-1759(95)00072-I
van Engeland M, Ramaekers FC, Schutte B, Reutelingsperger CP (1996) A novel assay to measure loss of plasma membrane asymmetry during apoptosis of adherent cells in culture. Cytometry 24(2):131–139. https://doi.org/10.1002/(SICI)1097-0320(19960601)24:2<131::AID-CYTO5>3.0.CO;2-M
Schutte B, Nuydens R, Geerts H, Ramaekers F (1998) Annexin V binding assay as a tool to measure apoptosis in differentiated neuronal cells. J Neurosci Methods 86(1):63–69. https://doi.org/10.1016/S0165-0270(98)00147-2
van Engeland M, Nieland LJ, Ramaekers FC, Schutte B, Reutelingsperger CP (1998) Annexin V-affinity assay: a review on an apoptosis detection system based on phosphatidylserine exposure. Cytometry 31(1):1–9. https://doi.org/10.1002/(SICI)1097-0320(19980101)31:1<1::AID-CYTO1>3.0.CO;2-R
Hoffmann MJ, Koutsogiannouli E, Skowron MA, Pinkerneil M, Niegisch G, Brandt A, Stepanow S, Rieder H, Schulz WA (2016) The new immortalized uroepithelial cell line HBLAK contains defined genetic aberrations typical of early stage urothelial tumors. Bladder Cancer 2(4):449–463. https://doi.org/10.3233/BLC-160065